Drug and alcohol dependence reports最新文献

{"title":"Prenatal cannabis screening and counseling practices by state recreational legalization status: A multi-state examination of PRAMS data (2017–2020)","authors":"Kara R. Skelton ,&nbsp;Stacey E. Iobst ,&nbsp;Sara E. Benjamin-Neelon","doi":"10.1016/j.dadr.2025.100385","DOIUrl":"10.1016/j.dadr.2025.100385","url":null,"abstract":"<div><h3>Objective</h3><div>Despite increased recreational cannabis legalization (RCL) in the US in recent years, little is known about cannabis advice received at prenatal care visits. We aimed to examine cannabis screening and counseling occurring at prenatal care visits, including adherence of advice to current clinical guidelines and variations by RCL status.</div></div><div><h3>Methods</h3><div>In this repeated cross-sectional study, we used 2017–2020 Pregnancy Risk Assessment Monitoring System data for 9 states to calculate weighted prevalence estimates of cannabis screening and advice received during prenatal care. We also examined adherence to the American College of Obstetricians and Gynecology’s clinical guidelines for cannabis use during pregnancy, including variations across RCL and self-reported prenatal cannabis use via chi-squared tests.</div></div><div><h3>Results</h3><div>In the sample (weighted N = 742,491), 20.53 % received cannabis advice that was adherent to clinical guidelines. Women in states with RCL more frequently reported being asked about cannabis use (78.66 % vs. 62.30 %; P &lt; 0.001), and reported being advised against cannabis use during pregnancy (44.29 % vs. 37.06 %; P &lt; 0.001) and lactation (31.03 % vs. 25.50 %; P &lt; 0.001) at a prenatal care visit than women residing in states without RCL. Similarly, women in states with RCL more frequently reported being advised to use cannabis prenatally (2.96 % vs 1.45 %, P &lt; 0.001). Women who reported any prenatal cannabis use were more likely to report being advised to use cannabis at a prenatal care visit in comparison to those who did not report prenatal cannabis use (10.10 % vs 1.16 %, P &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Given the variations in cannabis screening and advice occurring at prenatal care visits, findings underscore the importance of clinical practice that is consistent with current guidelines.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"17 ","pages":"Article 100385"},"PeriodicalIF":2.9,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145221293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Craving mediates the relationship between sleep quality and impaired control over drinking: A preliminary study","authors":"Erica N. Grodin ,&nbsp;Wave-Ananda Baskerville ,&nbsp;Lara A. Ray","doi":"10.1016/j.dadr.2025.100384","DOIUrl":"10.1016/j.dadr.2025.100384","url":null,"abstract":"<div><h3>Background</h3><div>Sleep disturbances are common in individuals with alcohol use disorder (AUD). Craving is a critical driver of alcohol use and return to drinking and is influenced by sleep. Craving may be a mechanism underlying the relationship between sleep disturbance and alcohol use, such that sleep disturbances result in higher craving, limiting control over alcohol use. This study examined craving as a mediator of the relationship between global sleep quality and impaired control over alcohol use.</div></div><div><h3>Methods</h3><div>Sixty-two (35M/27F) individuals with moderate-to-severe AUD participated in the study. Participants reported on past month sleep quality, craving for alcohol, impaired control over alcohol, and confidence to resist drinking in situations commonly precipitating alcohol use. Mediation models were conducted to evaluate craving as a mediator of the relationship between sleep quality and control over alcohol use.</div></div><div><h3>Results</h3><div>There was a significant indirect effect of craving on the relationship between sleep quality and failed control over drinking; confidence to resist drinking in negative affect situations, and confidence to resist drinking in social conflict situations.</div></div><div><h3>Conclusion</h3><div>Craving may be a mechanism through which sleep disturbances increase alcohol use. It is plausible that sleep disturbances reduce the ability for self-regulation, resulting in higher levels of craving and impaired ability to control alcohol use.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"17 ","pages":"Article 100384"},"PeriodicalIF":2.9,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145158460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The experience of individuals living with alcohol use disorder within palliative care and end of life services: A scoping review","authors":"Amélie Deschamps ,&nbsp;Andrée-Anne Légaré ,&nbsp;Anne-Marie Auger ,&nbsp;Natalia Muñoz Gómez ,&nbsp;Magaly Brodeur","doi":"10.1016/j.dadr.2025.100383","DOIUrl":"10.1016/j.dadr.2025.100383","url":null,"abstract":"<div><h3>Background</h3><div>Individuals with alcohol use disorder (AUD) often face stigma and fragmented care, contributing to the underutilization of palliative care (PC), despite overlapping clinical needs. Research on the specific experiences of AUD patients in PC and end of life (EOL) settings remains limited.</div></div><div><h3>Methods</h3><div>A scoping review following PRISMA guidelines was conducted across five databases. From 865 initial results, eight studies met inclusion criteria after full-text screening. Five of them were case reports. Eligible studies focused on the experiences of individuals living with AUD receiving PC or EOL services. Data extraction and narrative synthesis were then conducted.</div></div><div><h3>Results</h3><div>Patients with AUD in PC often experienced significant symptom burden, including poorly managed pain, depression, and alcohol withdrawal symptoms. AUD was frequently underrecognized by healthcare professionals, and details of alcohol use were inconsistently reported. Transitions to PC were often delayed, with limited patient involvement in EOL decision-making. Stigma, clinician discomfort, and lack of integrated addiction and PC approaches were recurring barriers to optimal care.</div></div><div><h3>Conclusion</h3><div>Given the limited research on the management of AUD within PC settings, this review highlights the need for further investigation. While the findings suggest potential priorities for future research and clinical practice, including improved AUD screening, enhanced training for PC providers, and earlier, patient-centered EOL planning. These findings should be interpreted with caution, as they are based on a small number of studies, most of which are case reports. Addressing these gaps may enhance the quality of care and outcomes for individuals with AUD at the EOL.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"17 ","pages":"Article 100383"},"PeriodicalIF":2.9,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145121224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Substance use, stigma, and coping in treatment: A qualitative study of participant perspectives","authors":"Kaylia Carroll ,&nbsp;Charles Ashley Warnock ,&nbsp;Ashlin Ondrusek ,&nbsp;Frances J. Griffith ,&nbsp;Adam Viera ,&nbsp;Noah Hopkins ,&nbsp;Carmen Muniz-Almaguer ,&nbsp;Cathy Jian ,&nbsp;Carson F. Ferrara ,&nbsp;Jessica Muilenburg ,&nbsp;Trace Kershaw","doi":"10.1016/j.dadr.2025.100380","DOIUrl":"10.1016/j.dadr.2025.100380","url":null,"abstract":"<div><h3>Background</h3><div>This study explores experiences of stigma in substance use treatment, coping strategies, and the contexts in which individuals feel stigmatized due to current or past substance use. Semi-structured interviews were conducted with 55 individuals enrolled in substance use treatment programs within two distinct geographical areas of the U.S., Northeast and Southeast. Data were collected from February to October 2023. Themes were organized by the Health Stigma and Discrimination Framework. Five themes were identified: 1.) <strong>Interpersonal drivers of stigma</strong> participants described feeling stigmatized by treatment staff, healthcare practitioners, and family; 2.) <strong>Substance- and method-specific stigmatization:</strong> participants reported feeling greater stigma from the use of criminalized substances and substances used intravenously, compared to non-criminalized substances and non-injection use methods; 3.) <strong>Coping approaches:</strong> participants identified active (e.g., prayer, meditation, exercise) and avoidant (e.g., laughing it off) strategies to manage stigmatizing experiences; 4.) <strong>Rejection of stereotypes:</strong> participants described empathetic views of people who use substances, even as they acknowledged that treatment environments often reinforce stigmatizing practices; 5.) <strong>Recovery-oriented care:</strong> participants felt less stigmatized and more comfortable with treatment providers with lived experience. Data for this study did not indicate differences by study site. Recommendations include prioritizing providers with lived experience, training healthcare workers in culturally responsive care, and integrating coping strategies and harm reduction into treatment to reduce stigma.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"17 ","pages":"Article 100380"},"PeriodicalIF":2.9,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145109624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and factors associated with tobacco and cannabis co-use in France: Results from a national representative survey","authors":"Tangui Barré ,&nbsp;Vincent Di Beo ,&nbsp;Camelia Protopopescu ,&nbsp;Emmanuel Lahaie ,&nbsp;Raphaël Andler ,&nbsp;Viêt Nguyen-Thanh ,&nbsp;Anne Pasquereau ,&nbsp;Patrizia Carrieri ,&nbsp;François Beck","doi":"10.1016/j.dadr.2025.100381","DOIUrl":"10.1016/j.dadr.2025.100381","url":null,"abstract":"<div><h3>Background and aims</h3><div>Tobacco use is a leading global risk factor for premature mortality. Cannabis-related harms are well documented, and its co-use with tobacco may hinder smoking cessation efforts. Moreover, tobacco use may amplify certain cannabis-related harms. To inform targeted interventions, we provided estimates of tobacco and cannabis co-use prevalence and correlates in France.</div></div><div><h3>Methods</h3><div>Using data from a 2021 nationwide representative sample of French population aged 18–64 years, we estimated the prevalence of tobacco and cannabis co-use. Co-use was defined as reporting daily cigarette smoking and at least monthly cannabis use. We used multinomial logistic regression models to identify factors associated with co-use.</div></div><div><h3>Results</h3><div>Among the 18,288 study participants, 71.8 % reported no use of cannabis or tobacco (‘no-use’ group), 22.3 % tobacco mono-use, 1.4 % cannabis mono-use, and 4.5 % co-use of both substances. Individuals who co-used reported a more frequent cannabis use than those who mono-used cannabis. Having financial difficulties was significantly associated with co-use, compared to tobacco and cannabis mono-use. After multivariable adjustment, the odds of co-use compared with ‘no-use’ was 2.3 times higher for participants with a poor health status, and 3.0 times higher for those with financial difficulties. Reporting a major depressive episode and unhealthy alcohol use were also significantly associated with co-use.</div></div><div><h3>Conclusions</h3><div>The clinical management of individuals who co-use tobacco and cannabis should include comprehensive assessments of physical and mental health, as well as alcohol consumption. Interventions to reduce co-use-related harms should also address the adverse social conditions experienced by this population.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"17 ","pages":"Article 100381"},"PeriodicalIF":2.9,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145109623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying Opioid Treatment Programs in Medicaid claims data to support quality improvement","authors":"Barrett Wallace Montgomery,&nbsp;Tami L. Mark,&nbsp;William Dowd,&nbsp;Chelsea Katz,&nbsp;Dylan DeLisle,&nbsp;Thanh Lu,&nbsp;Minglu Sun,&nbsp;Gary A. Zarkin","doi":"10.1016/j.dadr.2025.100379","DOIUrl":"10.1016/j.dadr.2025.100379","url":null,"abstract":"<div><div>In the United States, opioid treatment programs (OTPS) are the only provider type licensed to dispense methadone. Recently, U.S. regulators revised OTPs regulations with the aim of making OTP treatment more patient-centered and improving retention in treatment. Creating OTPs retention measures across all OTPs in the U.S. would give OTPs an important window into their retention rates relative to benchmarks and help identify which policies and procedures are most effective in improving retention. In the United States, insurance claims data are one of the few data sources available to create these metrics. Claims data include national provider identifiers; however, the Federal agency that regulates OTPs does not make public which national provider identifiers are associated with OTPs. This study investigated whether other variables captured in Medicaid claims could be used to identify OTPs. We identified two variables: methadone dispensing procedure codes and methadone clinic taxonomy codes, which identified 80 % and 66.8 % of the count of Medicaid-participating OTPs.Place of service and bill type codes were recently added to claims data and may be useful in the future. Methadone can reduce overdose deaths by 50 % but only if patients are maintained on methadone long enough. OTP metrics created with insurance claims data would facilitate efforts to improve retention and outcomes. This study identifies a practical way to identify OTPs in claims data to support such measures in the absence of a Federal list of OTPs and their national provider identifiers.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"17 ","pages":"Article 100379"},"PeriodicalIF":2.9,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145099741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isradipine enhancement of virtual reality cue exposure therapy is effective for individuals with higher baseline cue-induced craving","authors":"Santiago Papini ,&nbsp;Cara C. Young ,&nbsp;Richard A. Brown ,&nbsp;Haruka Minami ,&nbsp;Hitoshi Morikawa ,&nbsp;Michael W. Otto ,&nbsp;John D. Roache ,&nbsp;Jasper A.J. Smits","doi":"10.1016/j.dadr.2025.100378","DOIUrl":"10.1016/j.dadr.2025.100378","url":null,"abstract":"<div><h3>Introduction</h3><div>Evidence based treatments for smoking cessation have high recurrence rates. Targeting cue-induced craving, a strong predictor of smoking recurrence, may be critical to promoting sustained abstinence. We previously found that isradipine, an FDA-approved antihypertensive, enhanced the effect of virtual reality cue exposure therapy (VR-CET) on cue-induced craving. In this secondary analysis we tested whether this augmentation strategy was more beneficial for participants with high (relative to low) baseline cue-induced craving.</div></div><div><h3>Methods</h3><div>After a 24-h abstinence challenge, participants (N = 78) completed a single session of VR-CET with isradipine or placebo, and returned for a 24-h follow-up to repeat the procedure in a medication-free state. We conducted a moderator analysis to test the hypothesis that the effect of isradipine on cue-induced craving at follow-up would be larger among participants with higher (relative to lower) baseline cue-reactivity.</div></div><div><h3>Results</h3><div>In the model of cue-induced craving at follow-up, the Group ×  Baseline cue-reactivity interaction was significant, <em>p</em> = .045. Among participants with higher baseline cue-induced craving, isradipine resulted in a large, significant reduction in mean craving in the follow-up session (<em>M</em> difference = −18.17, 95 % CI [−31.38, −4.95], <em>p</em> = .01, <em>d</em> = −1.46). Among participants with lower baseline cue-induced craving, results were not significantly different across groups (<em>M</em> difference = 1.38, 95 % CI [−12.98, 15.75], <em>p</em> = .85, <em>d</em> = 0.11).</div></div><div><h3>Conclusions</h3><div>Results suggest isradipine enhances VR-CET, particularly for individuals with higher baseline levels of cue-induced craving. Future studies testing prevention strategies that target higher cue-induced craving with isradipine to reduce rates of smoking recurrence are warranted.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"17 ","pages":"Article 100378"},"PeriodicalIF":2.9,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with cannabis use disorder among Australians using prescribed and illicitly-sourced medical cannabis","authors":"Llewellyn Mills ,&nbsp;Jonathon C. Arnold ,&nbsp;Iain S. Mcgregor ,&nbsp;Nicholas Lintzeris","doi":"10.1016/j.dadr.2025.100362","DOIUrl":"10.1016/j.dadr.2025.100362","url":null,"abstract":"<div><h3>Background</h3><div>People who use cannabis medically do so more frequently than those who use nonmedically, potentially placing them at higher risk of cannabis use disorder (CUD). Prescription involves receiving guidance from doctors how best to administer medication; however, it remains unknown whether prescribed medical cannabis is associated with reduced incidence of CUD compared to illicit.</div></div><div><h3>Methods</h3><div>Data came from a 2022–23 online anonymous cross-sectional survey of Australians who had used medical cannabis. We examined differences between respondents who use Prescribed medical cannabis and respondents who use Illicit medical cannabis in demographic characteristics, patterns of use, and odds of meeting DSM-5 criteria for Any-CUD (≥2/11 criteria) and Moderate-Severe-CUD (≥4/11). Bayesian penalised regression models were used to identify the most important factors associated with CUD.</div></div><div><h3>Results</h3><div>Of 1796 respondents, 43 % met Any- and 17 % Moderate-Severe CUD criteria. In bivariate analyses, respondents who sourced illicit medical cannabis were more likely to meet criteria for Any CUD (53 % vs 41 %, OR=1.6 [CI: 1.3, 2.0]) and Moderate-Severe CUD (25 % vs 15 %, OR=2.0 [CI: 1.5, 2.6]) than those who were prescribed; however, with other factors controlled for, age, frequency-of-use, mental health, THC content, route of administration, and proportion of medical vs nonmedical cannabis use were more important correlates than whether medical cannabis was prescribed or illicitly sourced.</div></div><div><h3>Conclusions</h3><div>CUD is common amongst people who use medical cannabis. While CUD was less prevalent among people who obtained it on prescription than those who obtained it illicitly, other factors such as the concomitant use of cannabis for nonmedical reasons were a more important correlate with CUD.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"16 ","pages":"Article 100362"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144922364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opioid biomarkers in urine as reliable and valid correlates of opium use characteristics: A 10-year longitudinal assessment","authors":"Mahdokht Naghash ,&nbsp;Rebecca L. Shaner ,&nbsp;Hossein Poustchi ,&nbsp;Gholamreza Roshandel ,&nbsp;Katrice D. Williams ,&nbsp;Abraham Tuachi ,&nbsp;Farin Kamangar ,&nbsp;Paolo Boffetta ,&nbsp;Christian C. Abnet ,&nbsp;Elizabeth I. Hamelin ,&nbsp;Neal D. Freedman ,&nbsp;Reza Malekzadeh ,&nbsp;Arash Etemadi","doi":"10.1016/j.dadr.2025.100377","DOIUrl":"10.1016/j.dadr.2025.100377","url":null,"abstract":"<div><h3>Background</h3><div>Biomarkers can clarify the mechanistic bases of health effects associated with opiate use and improve evaluating dose-response relationships by quantifying the absorbed dose through different routes and patterns of use, supporting the generalizability of opium research findings to broader opioid use.</div></div><div><h3>Methods</h3><div>We recruited 449 individuals who used opium and 66 individuals who did not, 10 years after baseline evaluation in a cohort study. At both time points, we collected self-reported characteristics of opium use (route, frequency, type, and dose) and measured urinary concentrations of codeine, hydrocodone, hydromorphone, morphine, morphine-3-glucuronide, and morphine-6-glucuronide in spot urine samples. We used multivariate linear regression models to determine the independent effects of each opium use characteristic on biomarker concentrations. Reliability of biomarker concentrations over the 10-year interval was assessed using intraclass correlation coefficients (ICCs) from linear mixed-effect models.</div></div><div><h3>Results</h3><div>At the follow-up, 229 (51.0 %) subjects used opium by ingestion, which showed a significant shift compared with baseline (24.4 % ingestion). In adjusted models, opium ingestion, daily use, and presence of opioid use disorder (OUD) were associated with higher concentrations of all opioid biomarkers compared with opium smoking, non-daily use, and absence of OUD, respectively. All opioid biomarkers showed significant dose-response relationships relative to self-reported doses. Biomarker concentrations peaked when opium was used 3–4<!--> <!-->h before sample collection and declined afterwards, remaining detectable for several days. Biomarker measurements were reliable (ICCs between 0.69 and 0.78) over the 10-year interval.</div></div><div><h3>Conclusions</h3><div>Opioid biomarkers are valid markers of lifetime history, route, frequency, dose, and recency of opium use and OUD diagnosis, and demonstrate good long-term reliability.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"17 ","pages":"Article 100377"},"PeriodicalIF":2.9,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145007798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review investigating prenatal cannabis and tobacco co-exposure: Impacts on neonatal, behavioral, cognitive and physiological outcomes","authors":"Mathilde Argote ,&nbsp;Leah Hilson ,&nbsp;Maryam Sorkhou ,&nbsp;Rachel A. Rabin","doi":"10.1016/j.dadr.2025.100376","DOIUrl":"10.1016/j.dadr.2025.100376","url":null,"abstract":"<div><h3>Background</h3><div>Despite the high and increasing rates of cannabis and nicotine/tobacco product (NTP) use during pregnancy, the impact of their combined use on health outcomes in offspring remains poorly understood. Given the growing body of research on prenatal cannabis and NTP co-exposure and its effects on neonatal, behavioral, cognitive, and physiological outcomes in offspring, we conducted a systematic review to synthesize the existing literature and evaluate whether prenatal co-exposure results in additive and/or synergistic adverse effects compared to prenatal cannabis-only exposure and prenatal NTP-only exposure.</div></div><div><h3>Methods</h3><div>We searched Medline, Embase, and PsycINFO databases via OVID for human and animal studies examining the association between prenatal co-exposure and single-substance exposure on neonatal, behavioral, cognitive, and physiological outcomes in offspring.</div></div><div><h3>Results</h3><div>Of 3217 records identified, 46 articles were included in the review (human, n = 43; preclinical n = 3). For select neonatal outcomes, co-exposed infants exhibited a higher risk of compromised physical development and birth defects relative to infants with single-substance exposure. Behavioral outcomes, particularly emotion regulation/reactivity, and physiological outcomes demonstrated a similar pattern. In contrast, other neonatal outcomes (e.g., preterm birth and respiratory distress), and cognition were similar between the prenatal co-exposure and single-substance exposure groups.</div></div><div><h3>Conclusions</h3><div>This review suggests additive and/or synergistic adverse consequences associated with co-exposure on several outcomes in offspring relative to single substance exposure. These findings highlight the urgent need for prevention and treatment strategies addressing cannabis and NTP use in pregnant women. We discuss the limitations of the included studies and highlight key areas for future research.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"17 ","pages":"Article 100376"},"PeriodicalIF":2.9,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145007599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}